COMPANY

Sequella, Inc.

HQ: Rockville, MD source · sequella.com ↗ · Mid-Atlantic

Keywords: tuberculosis small molecule fungal infections infectious disease infectious diseases Helicobacter Pylori Infection PNU-100480 SQ109

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Trials (company is sponsor)50NIH grants

Timeline

2012-03 Trial start Phase 2: Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers source ↗
2011-08 Trial start Phase 2: PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay source ↗
2009-10 Trial start Phase 1: Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers source ↗
2009-04 Trial start Phase 1: Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults source ↗
2006-09 Trial start Phase 1: Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT01225640	PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay	Phase 2	Completed	2011-08	2011-12 (actual)
NCT01252108	Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers	Phase 2	Withdrawn	2012-03	2015-08 (actual)
NCT00990990	Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers	Phase 1	Completed	2009-10	2010-05 (actual)
NCT00871949	Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults	Phase 1	Completed	2009-04	2009-08 (actual)
NCT01585636	Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers	Phase 1	Completed	2006-09	2007-02 (actual)

NIH awards 50

Annual award amounts. Total $21.5M.

Mar 10, 2015 NIH award 5R01AI094458-05 FY2015: $728,339 awarded for that fiscal year; activity R01 (OTHER_NIH); PI EINCK, LEO; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Development of a New Diamine (SQ109) for the Trea source ↗
Feb 28, 2014 NIH award 5R01AI094458-04 FY2014: $725,317 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Development of a New Diamine (SQ109) f source ↗
Jul 11, 2013 NIH award 5R21DK092620-02 FY2013: $72,543 awarded for that fiscal year; activity R21 (OTHER_NIH); PI FERSTENBERG, LISA BETH; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Clinical Development of SQ109 for H. p source ↗
Mar 8, 2013 NIH award 5R01AI094458-03 FY2013: $725,821 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Development of a New Diamine (SQ109) f source ↗
Feb 5, 2013 NIH award 5R21AI096248-02 FY2013: $231,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI MULVEY, MATTHEW CHARLES; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. A Kit for Rapid AST of Mycobacterium source ↗
Jan 24, 2013 NIH award 5R43AI094844-02 FY2013: $297,897 awarded for that fiscal year; activity R43 (SBIR); PI NACY, CAROL A.; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. A New Therapeutic Regimen for MDR-TB source ↗
Jun 21, 2012 NIH award 1R21DK092620-01A1 FY2012: $313,110 awarded for that fiscal year; activity R21 (OTHER_NIH); PI FERSTENBERG, LISA BETH; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Clinical Development of SQ109 for H source ↗
Mar 15, 2012 NIH award 5R01AI094458-02 FY2012: $806,416 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Development of a New Diamine (SQ109) f source ↗
Mar 1, 2012 NIH award 1R21AI096248-01A1 FY2012: $208,950 awarded for that fiscal year; activity R21 (OTHER_NIH); PI MULVEY, MATTHEW CHARLES; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. A Kit for Rapid AST of Mycobacteri source ↗
Feb 29, 2012 NIH award 1R43AI094844-01A1 FY2012: $267,444 awarded for that fiscal year; activity R43 (SBIR); PI NACY, CAROL A.; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. A New Therapeutic Regimen for MDR-TB source ↗
Feb 29, 2012 NIH award 5R41AI094811-02 FY2012: $300,000 awarded for that fiscal year; activity R41 (STTR); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Targeting MtrAB of M. tuberculosis source ↗
Mar 30, 2011 NIH award 1R34AI094627-01 FY2011: $261,175 awarded for that fiscal year; activity R34 (OTHER_NIH); PI HORWITH, GARY; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Clinical development of SQ109 for MDR-TB source ↗
Mar 28, 2011 NIH award 1R01AI094458-01 FY2011: $730,895 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Development of a New Diamine (SQ109) f source ↗
Mar 1, 2011 NIH award 1R41AI094811-01 FY2011: $300,000 awarded for that fiscal year; activity R41 (STTR); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Targeting MtrAB of M. tuberculosis source ↗
Feb 25, 2011 NIH award 5R43AI088952-02 FY2011: $299,797 awarded for that fiscal year; activity R43 (SBIR); PI EINCK, LEO; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. SQ109 for treatment of MDR-TB source ↗
Aug 26, 2010 NIH award 5R43AI084211-02 FY2010: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. SQ641, new drug candidate to treat NTM infection source ↗
Aug 16, 2010 NIH award 5R44AI066442-04 FY2010: $850,410 awarded for that fiscal year; activity R44 (SBIR); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Novel mycobacterial translocase I inhibitors - a source ↗
Jan 22, 2010 NIH award 1R43AI088952-01 FY2010: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI EINCK, LEO; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. SQ109 for treatment of MDR-TB source ↗
Sep 21, 2009 NIH award 3R21AI070982-02S1 FY2009: $693,529 awarded for that fiscal year; activity R21 (OTHER_NIH); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Investigation of synergy between Rifampin source ↗
Aug 28, 2009 NIH award 1R43AI084211-01 FY2009: $294,661 awarded for that fiscal year; activity R43 (SBIR); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. SQ641, new drug candidate to treat NTM infection source ↗
Aug 26, 2009 NIH award 5R44AI066442-03 FY2009: $795,701 awarded for that fiscal year; activity R44 (SBIR); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Novel mycobacterial translocase I inhibitors - a source ↗
Jul 14, 2009 NIH award 3R44AI066442-02S1 FY2009: $19,372 awarded for that fiscal year; activity R44 (SBIR); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Novel mycobacterial translocase I inhibitors - source ↗
Feb 2, 2009 NIH award 1R43AI071664-01A2 FY2009: $305,054 awarded for that fiscal year; activity R43 (SBIR); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Advancing lead dipiperidine compound into source ↗
Aug 21, 2008 NIH award 2R44AI066442-02 FY2008: $793,901 awarded for that fiscal year; activity R44 (SBIR); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Novel mycobacterial translocase I inhibitors - a source ↗
Aug 7, 2008 NIH award 5R21AI070982-02 FY2008: $202,331 awarded for that fiscal year; activity R21 (OTHER_NIH); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Investigation of synergy between Rifampin a source ↗
Jul 2, 2008 NIH award 1R43AI077167-01 FY2008: $244,346 awarded for that fiscal year; activity R43 (SBIR); PI MULVEY, MATTHEW CHARLES; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Development of a phage-based nucleic acid source ↗
Aug 27, 2007 NIH award 1R21AI070982-01A1 FY2007: $247,500 awarded for that fiscal year; activity R21 (OTHER_NIH); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Investigation of synergy between Rifampin source ↗
Jul 28, 2006 NIH award 1R43AI066442-01A1 FY2006: $228,016 awarded for that fiscal year; activity R43 (SBIR); PI REDDY, VENKATA M; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Novel mycobacterial translocase I inhibitors-- source ↗
May 15, 2006 NIH award 1R34AI070790-01 FY2006: $107,250 awarded for that fiscal year; activity R34 (OTHER_NIH); PI PROTOPOPOVA, MARINA N; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. Moving a new anti-tubercular drug cand source ↗
Mar 10, 2006 NIH award 5U01AI057313-04 FY2006: $299,160 awarded for that fiscal year; activity U01 (OTHER_NIH); PI NACY, CAROL A.; recipient as written: SEQUELLA, INC., ROCKVILLE, MD. A Second-Generation Patch Test for Tuberculos source ↗